Cochrane · systematic review · CD009286
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
Legg, LA, Rudberg, A-S, Hua, X, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 2 · 28.6%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyFluoxetine versus control at end of treatment, for stroke recovery, using data from high quality trials only
Population: people with stroke recovery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disability (primary analysis) Fluoxetine vs control at end of treatment, | no estimate extracted | 5 studies · 5436 participants | High |
Independent on modified Rankin score (mRS 0 to 2) (primary analysis) Fluoxetine vs control at end of treatment, | RR 0.98 [0.93, 1.03] | 5 studies · 5926 participants | High |
Neurological deficit score Fluoxetine vs control at end of treatment, | no estimate extracted | 30 participants | Low Downgraded: imprecision |
Depression (continuous data) Fluoxetine vs control at end of treatment, | no estimate extracted | 4 studies · 5356 participants | High |
Death Fluoxetine vs control at end of treatment, | RR 1.01 [0.82, 1.24] | 6 studies · 6090 participants | Moderate Downgraded: imprecision |
Number of seizures Fluoxetine vs control at end of treatment, | RR 1.4 [1, 1.98] | 6 studies · 6080 participants | Moderate Downgraded: imprecision |
Bone fractures Fluoxetine vs control at end of treatment, | RR 2.35 [1.62, 3.41] | 6 studies · 6080 participants | High |
SSRI versus control at end of treatment, by SSRI for stroke recovery
Population: people with stroke recovery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disability (primary analysis) SSRI vs control at end of treatment, by SSRI | no estimate extracted | 2 studies · 2829 participants | Moderate Downgraded: imprecision |
Independent on modified Rankin score (mRS 0 to 2) (primary analysis) SSRI vs control at end of treatment, by SSRI | RR 1 [0.91, 1.09] | 3 studies · 3249 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Neurological deficit score SSRI vs control at end of treatment, by SSRI | no estimate extracted | 2 studies · 142 participants | Moderate Downgraded: imprecision |
Depression (continuous data) SSRI vs control at end of treatment, by SSRI | no estimate extracted | 2 studies · 2861 participants | Moderate |
Death SSRI vs control at end of treatment, by SSRI | RR 0.99 [0.79, 1.25] | 3 studies · 3254 participants | High |
Number of seizures SSRI vs control at end of treatment, by SSRI | RR 1.47 [0.99, 2.18] | 3 studies · 3275 participants | Moderate Downgraded: imprecision |
Gastrointestinal side effects SSRI vs control at end of treatment, by SSRI | RR 2.19 [1, 4.76] | 2 studies · 148 participants | Moderate Downgraded: imprecision |